Loss of PROSER1 impairs HSC function without compromising TET-mediated leukemia suppression. buff.ly/Jb0YFvl #hemesky

New Blood issue out now featuring: Association of Epstein-Barr virus genomic alterations with human pathologies buff.ly/2elfGXV

🌍 September is Sickle Cell Disease Awareness Month and together we are working to #ConquerSCD! 🔊 Measurable residual disease and maintenance therapy in acute myeloid leukemia, stemness and chemotherapy resistance in AML 🎧 buff.ly/RDIZMuC

🎙️ Just published a new episode of Blood Podcast: Epstein-Barr virus genomic variants in human disease states, somatic GATA1 mutations and leukemia in Down syndrome, and new definitions for high-risk multiple myeloma. Have a listen:

Racial disparities in the management of deep vein thrombosis from a nationwide hospitalization study buff.ly/JIsZLEm #hemesky

Prolonged MTR for induction and consolidation is a safe alternative treatment strategy for the management of PCNSL. buff.ly/vjYWZYU #hemesky

New Blood RCI issue out now featuring: Long-term mitapivat treatment is safe and efficacious in patients with sickle cell disease buff.ly/QXMhWzu

We are delighted to welcome Dr. Jennifer Amengual as new Associate Editor for Blood Neoplasia! Dr. Amengual is an Associate Professor of Medicine at Columbia University Irving Medical Center and a physician-scientist whose research focuses on developing targeted therapies for patients with lymphoma.

Given the high relapse rate after AZA discontinuation, long-term therapy may be required to maintain disease control. buff.ly/eqn6lct #hemesky

🌍 September is Sickle Cell Disease Awareness Month and together we are working to #ConquerSCD! 🔊Phosphoseryl-tRNA kinase inhibition in acute myeloid leukemia 🎧 buff.ly/Nl2YMzz #SCD #SCDC

Read about our @cclguk.bsky.social @littleprincesses.bsky.social funded research published in @bloodjournals.hematology.org . Well done Joe Cross and Lucy Field. Many thanks to Tom Milne and other collaborators. @oxfordpaediatrics.bsky.social @imm.ox.ac.uk ashpublications.org/bloodadvance...

HASPIN is a novel kinase dependency in AML regulating growth, transcription, and RNA-binding protein splicing functionality. buff.ly/2n1zRtD #hemesky

New Blood Advances issue out now featuring: Estimation of benefit to bispecific antibodies in US patients with lymphoma and multiple myeloma buff.ly/cwtor5a

CCR4 mutations and Moga-associated cAEs were related to better OS. buff.ly/Fi6QexZ #hemesky

Patterns of progression among 427 patients with smoldering myeloma diagnosed after 2014: importance of monitoring buff.ly/dVepKnY #hemesky

🌍 September is Sickle Cell Disease Awareness Month and together we are working to #ConquerSCD! 📚 Identifying pediatric patients with sickle cell disease at high risk of experiencing chronic pain after HSCT 📖 Read the full article here. buff.ly/AgBdW37

Racial disparities in multiple myeloma buff.ly/Z9eZ58D

ORR was 29% in heavily pretreated patients who had received prior BCMA-targeted therapy. buff.ly/zFa0r1C #hemesky

Age-related decline of DCAF8 expression in HSCs leads to functional defects. buff.ly/fd03KvX #hemesky

Late effects following CAR T cells and HCT in children and young adults with B-cell acute lymphoblastic leukemia buff.ly/3zmKnnB #hemesky

An ethical allocation scheme for scarce gene therapies in sickle cell disease and transfusion-dependent β-thalassemia buff.ly/z0D8Azi #hemesky

A locally adapted regimen for the treatment of pediatric ALL in Cambodia resulted in a 2-year RFS of 66%. buff.ly/CoUQShj #hemesky

🌍 September is Sickle Cell Disease Awareness Month and together we are working to #ConquerSCD! 🔊 Brentuximab vedotin, nivolumab, and chemotherapy in classical Hodgkin lymphoma 🎧https://buff.ly/E9RQy1v

This genetic risk is stronger in patients with NPM1 mutations. buff.ly/WyjEJoz #hemesky

🔊 Azacitidine holds promise in VEXAS syndrome; a step forward in precision blood matching; identifying a new vulnerability in TP53-mutated AML 🎧 buff.ly/fgf4LTP

Through drug repositioning, we found that ambroxol induces myeloma cell death by inhibiting late-stage autophagy. buff.ly/PKS4Scr #hemesky

🔊 Review Series on Acute Lymphoblastic Leukemia (ALL) 🎧 buff.ly/Na549mu

Longitudinal follow-up with trainees was key to support the growth of BMT in LMIC and build global partnerships. buff.ly/qik5LQ8 #hemesky

🌍 September is Sickle Cell Disease Awareness Month and together we are working to #ConquerSCD! 🔊 First-line asciminib for chronic myeloid leukemia, a new risk score for clonal cytopenia, and genotyped D-positive blood transfusion in sickle cell anemia 🎧 buff.ly/jmjBsdI

Meet Dr. Melody Smith, who joined Stanford University School of Medicine in 2021, where she established her independent lab. Her research focuses on cell-intrinsic and cell-extrinsic factors that impact CAR T cell efficacy and safety. Learn more about her and why she peer-reviews: buff.ly/9aizQ8Z

The age-adjusted rate of developing BIA-ALCL for women with BRCA was 16 times the rate of BIA-ALCL without BRCA. buff.ly/02ruLac

Moving beyond the eyeball test for fitness assessment in AML buff.ly/eXzBh2Q #hemesky

Early recognition of AL amyloidosis will improve the prognosis of these patients. buff.ly/pgX8Hgw #hemesky

New Blood issue out now featuring: Efficacy and safety of azacitidine for VEXAS syndrome: a large-scale retrospective study from FRENVEX buff.ly/kZKWnvM

🎙️ Just published a new episode of Blood Podcast: Review Series on Acute Lymphoblastic Leukemia (ALL). Have a listen:

Multifaceted cfDNA profiling in mantle cell lymphoma buff.ly/dnIdE8v #hemesky

🎙️ Just published a new episode of Blood Podcast: Azacitidine holds promise in VEXAS syndrome; a step forward in precision blood matching; identifying a new vulnerability in TP53-mutated AML. Have a listen:

🌍 September is Sickle Cell Disease Awareness Month and together we are working to #ConquerSCD! 🔊 Itacitinib in haploidentical hematopoietic cell transplantation, diagnosis and management of purpura fulminans 🎧 buff.ly/qM3itrZ

PDA scores (≥4) can recognize the onset of ICANS a median of 68 hours prior to clinical symptoms. buff.ly/BO4YPgA #hemesky

This genetic risk is stronger in patients with NPM1 mutations. buff.ly/WyjEJoz #hemesky

New Blood ICT issue out now featuring: Late effects following CAR T cells and HCT in children and young adults with B-cell acute lymphoblastic leukemia buff.ly/AewfIWH

Meet Dr. Steven Lane, a clinical hematologist in Brisbane, Australia, and head of a busy research group at the Queensland Institute of Medical Research. Learn more about him and why he serves as a peer reviewer for the Blood Journals portfolio: buff.ly/KkjOqYQ #PeerReviewWeek

“Optimizing” HLH diagnoses in patients with lymphoma buff.ly/WhIBaqA #hemesky

Identifying competencies is a critical step for implementing CBME in hematology residency programs. buff.ly/bT56C1Y #hemesky

The quadruplet regimen Dara-CTD was active and safe as frontline therapy in ASCT-eligible NDMM. buff.ly/iQBWuud #hemesky

Meet another one of our esteemed peer-reviewers for #PeerReviewWeek! Dr. Fernanda Orsi is a classical hematologist and Associate Professor in the Department of Pathology at the University of Campinas (UNICAMP), Brazil. Learn more about why she peer-reviews here: buff.ly/XhRsTXA

Reality bites: allocating gene therapy for hemoglobinopathies buff.ly/9ICNqxG #hemesky

🌍 September is Sickle Cell Disease Awareness Month and together we are working to conquer SCD! 📚 Ruxolitinib plus dexamethasone in newly diagnosed adult hemophagocytic lymphohistiocytosis 🎧 Listen to the full episode here. buff.ly/LyxrSuu

New study in #Blood VTH: We show that the AcuStar HIT-IgG (Werfen) CLIA is a reliable & fast ⏱️ diagnostic tool for #HIT with strong agreement vs anti-PFA/H ELISA (Hyphen) & SRA @davidmsmadja.bsky.social @hopitalpompidou.bsky.social @bloodjournals.hematology.org ashpublications.org/bloodvth/art...

We are excited to announce our new #NDLR2026 Meet-the-Editor session, with Editors-in-Chief, Prof Andrew Roberts, @bloodjournals.hematology.org and Prof @jancools.bsky.social, @hemasphere-journal.bsky.social who will share their invaluable insights on #publishing in high-impact #hematology journals.